KALA BIO, Inc. (NASDAQ:KALA – Get Free Report) gapped down before the market opened on Monday . The stock had previously closed at $3.9650, but opened at $3.62. KALA BIO shares last traded at $3.42, with a volume of 31,808 shares changing hands.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of KALA BIO in a research report on Friday, March 27th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $1,018.75.
View Our Latest Analysis on KALA
KALA BIO Stock Down 20.2%
KALA BIO (NASDAQ:KALA – Get Free Report) last issued its quarterly earnings results on Wednesday, April 15th. The company reported $43.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($8.50) by $51.50.
Institutional Trading of KALA BIO
A number of institutional investors and hedge funds have recently added to or reduced their stakes in KALA. Baker BROS. Advisors LP lifted its position in KALA BIO by 83.1% during the 4th quarter. Baker BROS. Advisors LP now owns 1,804,055 shares of the company’s stock worth $1,003,000 after acquiring an additional 818,962 shares during the period. Woodline Partners LP acquired a new stake in KALA BIO during the 1st quarter worth about $1,483,000. Jane Street Group LLC acquired a new stake in KALA BIO during the 4th quarter worth about $80,000. Virtu Financial LLC acquired a new stake in KALA BIO during the 4th quarter worth about $48,000. Finally, XTX Topco Ltd acquired a new stake in KALA BIO during the 2nd quarter worth about $62,000. Institutional investors and hedge funds own 24.61% of the company’s stock.
About KALA BIO
KALA Bio (NASDAQ: KALA) is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for ocular diseases. The company’s proprietary surface charge–based nanoparticle delivery platform is designed to enhance penetration and retention of therapeutic agents on the ocular surface. This technology is the basis for its lead product, Eysuvis (KPI-121 1.0%), an FDA-approved topical corticosteroid for short-term relief of ocular itching associated with allergic conjunctivitis.
Beyond its approved therapy, KALA Bio is advancing a pipeline of investigational drug candidates targeting inflammatory and degenerative eye conditions.
Read More
- Five stocks we like better than KALA BIO
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
Receive News & Ratings for KALA BIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KALA BIO and related companies with MarketBeat.com's FREE daily email newsletter.
